The effect of pandemic and COVID-19 vaccination campaigns on influenza and pneumococcal vaccination trends in patients with chronic diseases

Yıl 2022, Cilt: 5 Sayı: 2, 619 - 624, 15.03.2022

Osman İnan Enes Şahiner

https://doi.org/10.32322/jhsm.1062666

Öz

Aim: We planned this study to examine whether the measures taken against COVID-19 infection during the pandemic and COVID-19 vaccination process raise awareness about influenza and pneumococcal vaccines for patients in the risk group.
Material and Method: Patients over the age of 18 who were in the risk group according to CDC and had chronic diseases requiring influenza and pneumococcal vaccination were included in the study. A questionnaire consisting of seven questions was applied to all volunteers, showing their clinical demographic findings, their vaccination history, and whether the pandemic and COVID-19 vaccination processes contributed to the vaccination processes.
Results: It was found that 42.5% of the entire population had had a preventive vaccine before. With the COVID-19 pandemic, it was determined by the survey that 74.7% of the people would get their preventive vaccinations regularly from now on. After that, it was determined that the pandemic and COVID-19 vaccination processes were effective at a rate of 57.9% in the formation of this idea in the group that wanted to get a preventive vaccine.
Conclusion: As a result, the idea of having a preventive vaccination compared to the period before the pandemic increased during the pandemic period in relation to the events experienced in the pandemic. In this, it was determined that catching COVID-19 infection, hospitalization and intensive care unit admission and COVID-19 vaccination campaigns were effective in the cases in the risk group.

Anahtar Kelimeler

chronic kidney disease, diabetes, hearth disease, influenza, pneumococ, vaccine

Destekleyen Kurum

No

Proje Numarası

No

Kaynakça

• Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009; 9: 493-504.
• Boey L, Bosmans E, Ferreira LB, et al. Vaccination coverage of recommended vaccines and determinants of vaccination in at-risk groups. Human Vaccines & Immunotherapeutics 2020; 16: 2136-43.
• Doherty M, Schmidt-Ott R, Santos JI, et al. Vaccination of special populations: protecting the vulnerable. Vaccine 2016; 34: 6681-90.
• Sarda C, Palma P, Rello J. Severe influenza: overview in critically ill patients. Curr Opin Crit Care 2019; 25: 449-57.
• Sanz-Rojo S, Jiménez-García R, López-de-Andrés A, de Miguel-Diez J, Perez-Farinos N, Zamorano-León JJ. Influenza vaccination uptake among high-risk target groups and health care workers in Spain and change from 2017 to 2020. Vaccine 2021; 39: 7012-20.
• Centers for Disease Control and Prevention. https://www.cdc.gov/flu/highrisk/index.htm. Access date: 23.01.2022.
• Centers for Disease Control and Prevention. https://www.cdc.gov/pneumonia/prevention.html. Access date: 23.01.2022.
• Tan L, Theilacker C. 12 Direct and indirect benefits of to vaccinating adults with influenza and pneumococcal vaccines, especially in patients with chronic diseases. Adult Vaccinations: Changing the Immunization Paradigm 2019: 69.
• Hespanhol V, Bárbara C. Pneumonia mortality, comorbidities matter? Pulmonology 2020;26:123-9.
• Okoli GN, Lam OL, Racovitan F, et al. Seasonal influenza vaccination in older people: A systematic review and meta-analysis of the determining factors. PLoS One 2020; 15: e0234702.
• Dinleyici EC, Borrow R, Safadi MAP, van Damme P, Munoz FM. Vaccines and routine immunization strategies during the COVID-19 pandemic. Human Vaccines & Immunotherapeutics 2021; 17: 400-7.
• World Health Organization. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). Access date: 23.01.2022.
• World Health Organization. https://www.who.int/health-topics/pneumonia#tab=tab_1. Access date: 23.01.2022.
• Luyten J, Beutels P. The social value of vaccination programs: beyond cost-effectiveness. Health Affairs 2016; 35: 212-8.
• Giese C, Mereckiene J, Danis K, O’Donnell J, O’Flanagan D, Cotter S. Low vaccination coverage for seasonal influenza and pneumococcal disease among adults at-risk and health care workers in Ireland, 2013: The key role of GPs in recommending vaccination. Vaccine 2016; 34: 3657-62.
• Nichol KL, Zimmerman R. Generalist and subspecialist physicians' knowledge, attitudes, and practices regarding influenza and pneumococcal vaccinations for elderly and other high-risk patients: a nationwide survey. Archives of Internal Medicine 2001; 161: 2702-8.
• Nagata JM, Hernández-Ramos I, Kurup AS, Albrecht D, Vivas-Torrealba C, Franco-Paredes C. Social determinants of health and seasonal influenza vaccination in adults≥ 65 years: a systematic review of qualitative and quantitative data. BMC Public Health 2013; 13: 1-25.
• Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999; 281: 908-13.
• Nichol KL, Mac Donald R, Hauge M. Factors associated with influenza and pneumococcal vaccination behavior among high-risk adults. J General Int Med 1996; 11: 673-7.
• Çiftci F, Şen E, Demir N, Çiftci O, Erol S, Kayacan O. Beliefs, attitudes, and activities of healthcare personnel about influenza and pneumococcal vaccines. Human Vaccines & Immunotherapeutics 2018; 14: 111-7.
• Altay M, Ateş İ, Altay FA, Kaplan M, Akça Ö, Özkara A. Does education effect the rates of prophylactic vaccination in elderly diabetics? Diabetes Research and Clinical Practice 2016; 120: 117-23.
• Stancu MA, Barratt J, Anaya MB. A Canadian perspective on pneumonia vaccination among at-risk groups: Increasing relevance in a pandemic era. Expert Meeting Report 2020.